Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Rhabdoid Tumor 6Medulloblastoma 6Glioma 6Wilms Tumor 5Sarcoma 5Rhabdomyosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Lymphoma, Non-Hodgkin 5Histiocytosis, Langerhans-Cell 5Hepatoblastoma 5Ependymoma 5Central Nervous System Neoplasms 5Osteosarcoma 4Sarcoma, Ewing 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Multiple Myeloma 2Lung Neoplasms 2Burkitt Lymphoma 2Xanthogranuloma, Juvenile 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rectal Neoplasms 1Non functioning pancreatic endocrine tumor 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Histiocytic Sarcoma 1

Interventions

Nivolumab 4Ipilimumab 3Specimen Handling 2Magnetic Resonance Spectroscopy 2Cetuximab 2tazemetostat 1pembrolizumab 1atezolizumab 1X-Rays 1Tiragolumab 1Radiosurgery 1Proton Therapy 1Phantoms, Imaging 1Fluorodeoxyglucose F18 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Chordoma × Phantoms, Imaging × Clear all
NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡